Clinical Trial Update: CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis [Phase 3]

View source ↗

Summary

The CHABLIS-SC2 Phase 3 trial of subcutaneous blisibimod for systemic lupus erythematosus (with or without nephritis) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• blisibimod (blisibimod)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: WITHDRAWN